P4.11E.06 Envafolimab Combined with Recombinant Human Endostatin and Chemotherapy as First-Line Treatment for Advanced Squamous NSCLC

MLA

Liu, L., et al. “P4.11E.06 Envafolimab Combined with Recombinant Human Endostatin and Chemotherapy as First-Line Treatment for Advanced Squamous NSCLC.” Journal of Thoracic Oncology, vol. 19, no. 10, Number 10 Supplement 1, Oct. 2024, p. S397. EBSCOhost, https://doi.org/10.1016/j.jtho.2024.09.719.

APA

Liu, L., Liu, J., Liu, Y., Yu, X., Li, S., Li, B., Guo, S., Zhang, Y., Wang, Y., Zheng, T., Han, W., Xie, Y., Zhou, L., Zhang, J., Zhao, Y., Li, Y., Hu, Y., Wang, J., & Cao, H. (2024). P4.11E.06 Envafolimab Combined with Recombinant Human Endostatin and Chemotherapy as First-Line Treatment for Advanced Squamous NSCLC. Journal of Thoracic Oncology, 19(10, Number 10 Supplement 1), S397. https://doi.org/10.1016/j.jtho.2024.09.719

Chicago

Liu, L., J. Liu, Y. Liu, X. Yu, S. Li, B. Li, S. Guo, et al. 2024. “P4.11E.06 Envafolimab Combined with Recombinant Human Endostatin and Chemotherapy as First-Line Treatment for Advanced Squamous NSCLC.” Journal of Thoracic Oncology 19 (10, Number 10 Supplement 1): S397. doi:10.1016/j.jtho.2024.09.719.